Topic List : Stem Cells
Adult stem cells channel early development
New research from Stanford shows that skeletal stem cells in mice assume a more primitive developmental state in response to extensive regeneration needs and environmental cues.
Human skeletal stem cell identified
Identification of the human skeletal stem cell by Stanford scientists could pave the way for regenerative treatments for bone fractures, arthritis and joint injuries.
New protein essential for making stem cells
The discovery by Stanford scientists drills a peephole into the black box of cellular reprogramming and may lead to new ways to generate induced pluripotent stem cells in the laboratory.
Study solves mystery of genetic mutation
Stanford researchers used genetic-editing tools and stem cell technology to uncover whether a genetic mutation linked to a heart rhythm disorder was benign or pathogenic.
Neurons quickly generated from blood
Fresh or frozen human blood samples can be directly transformed into patient-specific neurons to study disorders such as schizophrenia and autism, Stanford researchers find.
Can stem cells treat urinary incontinence?
Bertha Chen, MD, professor of obstetrics and gynecology, will receive nearly $6 million from the state stem cell agency to support research into the use of stem cells to treat urinary incontinence.
$11.9 million for anti-leukemia trial
The California Institute for Regenerative Medicine awarded Stanford researcher Crystal Mackall a grant to study immune cells genetically modified to attack two proteins on leukemia and lymphoma cells.
How liver regenerates itself
A subset of liver cells with high levels of telomerase renews the organ during normal cell turnover and after injury, according to Stanford researchers. The cells may also give rise to liver cancer.
Protein clumps affect neural stem cells
Young, resting neural stem cells have large protein clumps often associated with neurodegeneration. As stem cells age, the aggregates inhibit their ability to make new neurons, Stanford researchers say.
Antibody treatment for ‘bubble boy’ disease
In a clinical trial, participants were given an antibody to CD117, a cell surface marker, in an effort to wipe out their defective blood stem cells without high-risk chemotherapy or radiation.